These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 39084081)
41. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair. Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938 [TBL] [Abstract][Full Text] [Related]
42. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma. Liu JR; Yu CW; Hung PY; Hsin LW; Chern JW Biochem Pharmacol; 2019 May; 163():458-471. PubMed ID: 30885763 [TBL] [Abstract][Full Text] [Related]
43. Drugging the HDAC6-HSP90 interplay in malignant cells. Krämer OH; Mahboobi S; Sellmer A Trends Pharmacol Sci; 2014 Oct; 35(10):501-9. PubMed ID: 25234862 [TBL] [Abstract][Full Text] [Related]
44. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer. Zhang J; Chen X; Chen G; Wang H; Jia L; Hao Y; Yao D Int J Biol Macromol; 2023 Nov; 251():126348. PubMed ID: 37586623 [TBL] [Abstract][Full Text] [Related]
45. SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules. Wang F; Zheng L; Yi Y; Yang Z; Qiu Q; Wang X; Yan W; Bai P; Yang J; Li D; Pei H; Niu T; Ye H; Nie C; Hu Y; Yang S; Wei Y; Chen L Mol Cancer Ther; 2018 Apr; 17(4):763-775. PubMed ID: 29610282 [TBL] [Abstract][Full Text] [Related]
47. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors. Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899 [TBL] [Abstract][Full Text] [Related]
48. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors. Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953 [TBL] [Abstract][Full Text] [Related]
49. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity. Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013 [TBL] [Abstract][Full Text] [Related]
50. Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance. Jo H; Shim K; Jeoung D Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076996 [TBL] [Abstract][Full Text] [Related]
51. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity. Negmeldin AT; Pflum MKH Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461 [TBL] [Abstract][Full Text] [Related]
52. Odd-chain fatty acids as novel histone deacetylase 6 (HDAC6) inhibitors. Ediriweera MK; To NB; Lim Y; Cho SK Biochimie; 2021 Jul; 186():147-156. PubMed ID: 33965456 [TBL] [Abstract][Full Text] [Related]
53. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease. Benoy V; Vanden Berghe P; Jarpe M; Van Damme P; Robberecht W; Van Den Bosch L Neurotherapeutics; 2017 Apr; 14(2):417-428. PubMed ID: 27957719 [TBL] [Abstract][Full Text] [Related]
54. Discovery of a fluorescent probe with HDAC6 selective inhibition. Zhang Y; Yan J; Yao TP Eur J Med Chem; 2017 Dec; 141():596-602. PubMed ID: 29102179 [TBL] [Abstract][Full Text] [Related]
55. Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat. Wu CP; Hung CY; Lusvarghi S; Chang YF; Hsiao SH; Huang YH; Hung TH; Yu JS; Ambudkar SV Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807514 [TBL] [Abstract][Full Text] [Related]
56. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors. Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291 [TBL] [Abstract][Full Text] [Related]
57. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes. Osko JD; Christianson DW Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087 [TBL] [Abstract][Full Text] [Related]
58. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity. Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103 [TBL] [Abstract][Full Text] [Related]
59. Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group. Linciano P; Pinzi L; Belluti S; Chianese U; Benedetti R; Moi D; Altucci L; Franchini S; Imbriano C; Sorbi C; Rastelli G J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2080-2086. PubMed ID: 34583596 [TBL] [Abstract][Full Text] [Related]
60. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019). Shen S; Kozikowski AP Expert Opin Ther Pat; 2020 Feb; 30(2):121-136. PubMed ID: 31865813 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]